Camrelizumab
-
HUTCHMED Advances Surufatinib/Camrelizumab Combo to Phase III for Untreated Pancreatic Cancer
HUTCHMED has advanced its pancreatic cancer program to Phase III, initiating a trial for a combination therapy of surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine (S+C+AG) for metastatic PDAC in China. Promising Phase II results showed significant improvements in progression-free survival and objective response rate compared to the standard chemotherapy regimen. The Phase III trial will evaluate overall survival as the primary endpoint in approximately 400 additional patients.
